Page 22 - DIAGEN-EN

Hematology primeFISH Products

HEMATOLOGY
PANEL

17-093 IGH-MYEOV t(11;14)

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin Unlike IGH rearrange ments in other neoplasms,
lymphoma (NHL) with an aggressive clini cal course. it those found in MM have IGH breakpoints
is genetically characterized by t(11;14)(q13;q32) found predominantly in the C/J region, placing the MYEOV
in ap-proximately 95% of MCL patients. Less frequently, gene under the control of the 3’ Eal enhancer when in
t(11;14) can also be detected in B-cell prolymphocytic the MYEOV state. in contrast to CCND1 translocations,
leukemia, my elomas, and chronic lymphocytic the Eµ enhancer controls CCND1 expression. MYEOV
leukemia. The t(11;14)(q13;q32) translocation is the most overexpression may be a possible prognostic factor in
common translocation in MM, occurring in MM.
approximately 15% of cases.

TRANSLOCATION

SHGC-140404 D11S2927
3' 5'
Cent Tel
MYEOV

523 kb
11q13.3 NORMAL
RH98285 SHGC-106213
3' 5'
Cent Tel
IGH
TRANSLOCATION
1.5 mb

14q32.33

(Not to scale)

www.diagen.com.tr References
Ronchetti et al., Blood 1999 93(4):1330-1337
Moreaux et al., Exp Haematol 2010;38(12):1189-1198
Bentz et al (2004) Canc Cytopath 102:124-131
Fonseca et al., Leukemia 2009;23(12):2210-2221
Jares et al (2012) J Clin Invest 122:3416-3423

22 PRODUCT CATALOGUE